on NANOBIOTIX (EPA:NANO)
Nanobiotix Advances Curadigm Nanoprimer Platform for Improved Drug Delivery
Nanobiotix has announced significant developments in its Curadigm Nanoprimer platform, aiming to enhance the delivery of intravenous therapeutic agents. The company has filed four new patent applications to boost its intellectual property portfolio and support both internal product development and external collaborations.
The Curadigm Nanoprimer, based on lipid nanoparticles, temporarily occupies liver pathways, reducing therapeutic clearance and potentially improving drug efficacy. Recent preclinical data presented at the 2025 Partnership Opportunities in Drug Delivery conference demonstrated enhanced immune responses when combining the Nanoprimer with RNA and peptide-based vaccines.
Nanobiotix is also advancing Chemistry, Manufacturing, and Controls activities to bolster both internal and collaborative efforts. With multiple material transfer agreements underway, the company is set to leverage its platform for strategic collaborations in the biotechnology sector.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news